TUMOR NECROSIS FACTOR-α MEMBRANE-BOUND AND SOLUBLE RECEPTORS IN NORM AND IN RHEUMATOID ARTHRITIS
Abstract
TNFα — a multifunctional pleiotropic cytokine, considered to have a special significance in the immunopathogenesis of rheumatoid arthritis. Herewith the effectiveness of immunomodulatory cytokine and its role in the development of pathological states of the organism may depend largely on the content of soluble receptors and expression of membrane-bound receptors. The study shows several significant differences not only in the percentage of cells with. TNFα receptors, but also in the absolute number of receptors expressed on cells from different subsets of immunocompetent cells in health and in rheumatoid arthritis, establishes correlation relationships of these parameters with serum contents of the cytokine and its soluble receptors. The mechanisms and the role of changes in the expression of TNFα receptors in different subsets of leukocytes in immunopathological state and in compare with healthy donors are discussed.
About the Authors
A. A. Alshevskaya
Research Institute of Clinical Immunology SB RAMS
Russian Federation
Russian Federation
F. F. Vasiliev
Research Institute of Clinical Immunology SB RAMS
Russian Federation
Russian Federation
J. A. Lopatnikova
Research Institute of Clinical Immunology SB RAMS
Russian Federation
Russian Federation
S. V. Sennikov
Research Institute of Clinical Immunology SB RAMS
Russian Federation
Russian Federation
References
1. Александрова Ю.Н. О системе цитокинов // Педиатрия. — 2007. — Т. 86, № 3. — С. 10—15.
2. Мазуров В.И. Болезни суставов. — СПб.: СпецЛит, 2008. — 408 с.
3. Böyum A. Separation of leucocytes from blood and bone marrow // Scand. J. Clin. Lab. Invest. — 1968. — Vol. 21. — P. 97.
4. Camussi G., Albano E., Tetta C., Bussolin F. The molecular action of tumor necrosis factor-a // Eur. J. Biochem. — 1991. — Vol. 202. — P. 3—14.
5. Dayer J.M. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases // Best Pract. Res. Clin. Rheumatol. — 2004. — Vol. 18, N 1. — P. 31—45.
6. Distler O., Müller-Ladner U., Schölmerich J., Gay R.E. et al. Rheumatoid arthritis: new molecular and cellular aspects // Med Klin (Munich). — 1999. — Vol. 94, N 12. — P. 673 — 680.
7. Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological crossreactivity with cell surface tumor necrosis factor receptors // J. Biol. Chem. — 1990. — Vol. 265, N 3. — P. 1531 — 1536.
8. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level // FEBS Lett. — 1991. — Vol. 285, N 2. — P. 199 — 212.
9. Furst D.E. Development of TNF inhibitor therapies for the treatment of rheumatoid arthritis // Clin. Exp. Rheumatol. — 2010. — Vol. 28, N 3. — P. 5 — 12.
10. Kokkonen H., Söderström I., Rocklöv J., Hallmans G. et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis // Arthritis Rheum. — 2010. — Vol. 62, N 2. — P. 383 — 391.
11. Kwiatkowski D., Hill A.V., Sambou I., Twumasi P. et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria // Lancet. — 1990. — Vol. 336. — P. 1201 — 1204.
12. Lotz M., Setareh M., von Kempis J., Schwarz H. The nerve growth factor/tumor necrosis factor receptor family // J. Leukoc. Biol. — 1996. — N 60. — P. 1—7.
13. Song Y.W., Kang E.H. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies // QJM. — 2010. — Vol. 103, N 3. — P. 139 — 146.
Review
For citations:
Alshevskaya A.A., Vasiliev F.F., Lopatnikova J.A., Sennikov S.V. TUMOR NECROSIS FACTOR-α MEMBRANE-BOUND AND SOLUBLE RECEPTORS IN NORM AND IN RHEUMATOID ARTHRITIS. Acta Biomedica Scientifica. 2012;(3(2)):23-28. (In Russ.)
Views:
461
.png)
Email this article 
